A Phase 2 interventional study of MEDI4736 and Tremelimumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck, sponsored by AstraZeneca. Completed at 125 sites in 15 countries. Open to participants aged 18 Years to 96 Years. Per ClinicalTrials.gov, last updated 2020-09-29.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have progressed during or after treatment with a platinum containing regimen for recurrent/metastatic disease.
This is a randomized, open-label, multi-center, global, Phase II study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy, MEDI4736 monotherapy and tremelimumab monotherapy in the treatment of patients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck (SCCHN) who have progressed during or after treatment with only 1 systemic palliative regimen for recurrent or metastatic disease, that must have contained a platinum agent.
Patients will be randomized in a stratified manner according to prognostic factors, including human papillomavirus (HPV) status and smoking status to achieve a balance between treatments for each of the factors. Patients will be randomized in a 1:1:2 fashion to receive MEDI4736 monotherapy, tremelimumab monotherapy, or MEDI4736 + tremelimumab combination.
All treatments will be administered beginning on Day 0 for 12 months or until confirmed progression of disease; unless, in the Investigator's opinion, the patient continues to receive benefit from the treatment), initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. Patients with confirmed progression of disease who, in the Investigator's opinion, continue to receive benefit from their assigned investigational product and who meet the criteria for treatment in the setting of progression of disease may continue to receive their assigned investigational product treatment for a maximum of 12 months after consultation with the Sponsor and at the Investigator's discretion. The monotherapy arms (tremelimumab and MEDI4736) should be discontinued if there is confirmed progression of disease following a previous response in target lesions (complete response or partial response).
Tumor assessments will be performed using computed tomography or magnetic resonance imaging. Efficacy for all patients will be assessed by objective tumor assessments every 8 weeks (q8w) for the first 48 weeks (relative to the date of the first infusion) then q12w in patients who have disease control after 12 months until confirmed objective disease progression.
Following completion or discontinuation of treatment, patients will enter a follow-up period.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MEDI4736 monotherapy
Drug: MEDI4736
Tremelimumab monotherapy
Drug: Tremelimumab
MEDI4736 + Tremelimumab combination therapy
Drug: MEDI4736 + Tremelimumab
MEDI4736 monotherapy
Tremelimumab monotherapy
Drug pages: Durvalumab · Tremelimumab
MEDI4736 + Tremelimumab combination therapy
Objective Response Rate at 6 Months
Objective response rate, primary analysis, based on BICR assessments according to RECIST v1.1. The number (%) of patients with a response excludes unconfirmed responses
Time frame: After 6 months
Objective Response Rate at 12 Months
Objective response rate (per RECIST 1.1 as assessed by blinded independent central review \[BICR\]) is defined as the number (%) of patients with a confirmed complete response or confirmed partial response and will be based on all treated patients who are PD-L1-positive with measurable disease at baseline per BICR. Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1. criteria are: Complete response \[CR\] = disappearance of all target lesions since baseline; and partial response \[PR\] = at least a 30% decrease in the sum of the diameters of target lesions.
Time frame: After 12 months
Best Objective Response
The best response a patient has had during their time in the study
Time frame: After 12 months
Duration of Response - Participants Remaining in Response
Participants remaining in response - based on BICR assessments according to RECIST v1.1. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off.
Time frame: After 12 months
Time to Response
Time to response in patients with objective response based on BICR assessments according to RECIST 1.1
Time frame: After 12 months
Time to Onset of Response From First Dose
Time to onset of response in patients with objective response based on BICR assessments according to RECIST 1.1
Time frame: After 12 months
Disease Control Rate (DCR)
Disease control rate (DCR) at 6 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD). -Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following randomization. -Method 2: Patients who had a best objective response of CR or PR in the first 24 weeks or who had demonstrated SD for a minimum interval of 16 weeks following randomization.
Time frame: After 6 months
Disease Control Rate (DCR)
Disease control rate (DCR) at 12 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD). -Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following randomization. -Method 2: Patients who had a best objective response of CR or PR in the first 24 weeks or who had demonstrated SD for a minimum interval of 16 weeks following randomization.
Time frame: After 12 months
Progression-free Survival (PFS)
Progression status at 6 months based on BICR assessments according to RECIST v1.1 at time of Progression Free Survival (PFS) analysis. Progression was defined as the time from the data of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. -Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. -Progression death refers to death in the absence of RECIST 1.1 progression.
Time frame: After 6 months
Progression-free Survival (PFS)
Progression status at 12 months based on BICR assessments according to RECIST v1.1 at time of Progression Free Survival (PFS) analysis. Progression was defined as the time from the data of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. -Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. -Progression death refers to death in the absence of RECIST 1.1 progression.
Time frame: After 12 months
Overall Survival
Survival status at time of overall survival analysis. 'Still in survival follow-up' includes patients known to be alive at data cut-off. 'Terminated prior to death' includes patients with unknown survival status or patients who were lost to follow-up.
Time frame: After 12 months
Quality of Life
Improvement in quality of life was assessed using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires: -The impact of treatment on Health-Related Quality of Life, functioning, and symptoms was evaluated using the EORTC QLQ-C30 v3. -Head and neck cancer-specific symptoms were evaluated using the EORTC QLQ-H\&N35. The symptom and QoL/function improvement rate was defined as the number (%) of patients with 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (a decrease from baseline score ≥10 or EORTC QLQ-C30 scales) in that symptom/function from baseline. For QLQ-H\&N35A a minimum clinically meaningful change was defined as a change in the score from baseline of \>10 for scales/items
Time frame: After 12 months
Duration of Response
Duration of objective response in patients with objective response based on BICR assessments according to RECIST v1.1. Duration of response was the time from the first documentation of Complete response/Partial response (which was subsequently confirmed) until the date of progression, death, or the last evaluable RECIST assessment for patients that did not progress. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off (per RECIST v1.1 as assessed by BICR).
Time frame: After 12 months
127 sites in 15 countries enrolled and screened patients. The study was conducted and managed by PRA, a contract research organization.
| Milestone | MEDI4736 AND TREMELIMUMAB COMBINATION | MEDI4736 | Tremelimumab |
|---|---|---|---|
| Started | 133 | 67 | 67 |
| Completed | 11 | 7 | 0 |
| Not completed | 122 | 60 | 67 |
| Withdrew: Death, pi/sponsor decision, med history | 0 | 1 | 4 |
| Withdrew: Withdrawal by subject | 3 | 3 | 6 |
| Withdrew: Condition under investigation worsened | 100 | 50 | 46 |
| Withdrew: Adverse event | 17 | 2 | 8 |
| Withdrew: Study specific discontinuation criteria | 2 | 2 | 1 |
| Withdrew: Not treated | 0 | 2 | 2 |
Objective response rate, primary analysis, based on BICR assessments according to RECIST v1.1. The number (%) of patients with a response excludes unconfirmed responses
| % participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab |
|---|---|---|---|
| Objective Response Rate at 6 Months | 7.7 (3.75 to 13.69) | 9.2 (3.46 to 19.02) | 1.6 (0.04 to 8.53) |
Objective response rate (per RECIST 1.1 as assessed by blinded independent central review \[BICR\]) is defined as the number (%) of patients with a confirmed complete response or confirmed partial response and will be based on all treated patients who are PD-L1-positive with measurable disease at baseline per BICR. Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1. criteria are: Complete response \[CR\] = disappearance of all target lesions since baseline; and partial response \[PR\] = at least a 30% decrease in the sum of the diameters of target lesions.
| % participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab |
|---|---|---|---|
| Overall | 7.8 (3.78 to 13.79) | 9.2 (3.46 to 19.02) | 1.6 (0.04 to 8.53) |
| Current smoking/nicotine status - Total | 13.6 (2.91 to 34.91) | 14.3 (0.36 to 57.87) | 14.3 (0.36 to 57.87) |
| Current smoking/nicotine status - >10 pack years | 15.0 (3.21 to 37.89) | 14.3 (0.36 to 57.87) | 16.7 (0.42 to 64.12) |
| Current smoking/nicotine status - ≤10 pack years | 0 (0.00 to 84.19) | — | 0 (0.00 to 97.50) |
| Former smoking/nicotine status -Total | 6.8 (2.54 to 14.25) | 8.2 (2.27 to 19.60) | 0 (0.00 to 8.04) |
| Former smoking/nicotine status - >10 pack years | 5.2 (1.08 to 14.38) | 9.1 (1.92 to 24.33) | 0 (0.00 to 10.89) |
| Former smoking/nicotine status - ≤10 pack years | 10.0 (2.11 to 26.53) | 6.3 (0.16 to 30.23) | 0 (0.00 to 26.46) |
| Smoking/nicotine status - Never | 5.3 (0.13 to 26.03) | 11.1 (0.28 to 48.25) | 0 (0.00 to 26.46) |
| HPV status - Positive | 5.4 (0.66 to 18.19) | 16.7 (3.58 to 41.42) | 0 (0.00 to 18.53) |
| HPV status - Negative | 8.7 (3.83 to 16.42) | 6.4 (1.34 to 17.54) | 2.2 (0.06 to 11.77) |
The best response a patient has had during their time in the study
| % participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Response - Total | 7.8 | 9.2 | 1.6 | 6.6 |
| Response - Complete response (CR) | 0 | 0 | 0 | 0 |
| Response - Partial response (PR) | 7.8 | 9.2 | 1.6 | 6.6 |
| Non-response (NR) - Total | 92.2 | 90.8 | 98.4 | 93.4 |
| NR - Stable disease (SD) >=6 months (24 weeks) | 5.4 | 6.2 | 0 | 4.3 |
| NR - Unconfirmed complete or partial response (PR) | 1.6 | 0 | 0 | 0.8 |
| NR - Stable disease | 3.9 | 6.2 | 0 | 3.5 |
| NR - Progression | 64.3 | 64.6 | 69.8 | 65.8 |
| NR - Progression-RECIST 1.1 progression | 45.7 | 46.2 | 54.0 | 47.9 |
| NR - Progression-Death | 18.6 | 18.5 | 15.9 | 17.9 |
| NR - Not evaluable-Total | 22.5 | 20.0 | 28.6 | 23.3 |
| NR - Not evaluable-SD <6 months (24 weeks) | 20.2 | 16.9 | 19.0 | 19.1 |
| NR - Not evaluable-Incomplete post baseline tests | 2.3 | 3.1 | 9.5 | 4.3 |
Participants remaining in response - based on BICR assessments according to RECIST v1.1. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off.
| % participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Percentage remaining in response-3 months | 90.0 | 100 | 100 | 94.1 |
| Percentage remaining in response-6 months | 70.0 | 66.7 | 100 | 70.6 |
| Percentage remaining in response-9 months | 58.3 | 66.7 | NA | 64.2 |
| Percentage remaining in response-12 months | 46.7 | NA | NA | 53.5 |
| Percentage of ongoing response | 50.0 | 66.7 | 100 | 58.8 |
Time to response in patients with objective response based on BICR assessments according to RECIST 1.1
| % participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Number of responders | 100 | 100 | 100 | 100 |
| Week 8, where response is first observed | 10.0 | 0 | 0 | 5.9 |
| Week 9, where response is first observed | 50.0 | 16.7 | 100 | 41.2 |
| Week 16, where response is first observed | 10.0 | 16.7 | 0 | 11.8 |
| Week 17, where response is first observed | 10.0 | 16.7 | 0 | 11.8 |
| Week 20, where response is first observed | 0 | 16.7 | 0 | 5.9 |
| Week 24, where response is first observed | 10.0 | 16.7 | 0 | 11.8 |
| Week 25, where response is first observed | 10.0 | 16.7 | 0 | 11.8 |
Time to onset of response in patients with objective response based on BICR assessments according to RECIST 1.1
| Months | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Time to Onset of Response From First Dose | 2.0 (2 to 6) | 4.1 (2 to 6) | 1.8 (1.8 to 2) | 3.5 (2 to 6) |
Disease control rate (DCR) at 6 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD). -Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following randomization. -Method 2: Patients who had a best objective response of CR or PR in the first 24 weeks or who had demonstrated SD for a minimum interval of 16 weeks following randomization.
| % participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| METHOD 1: Disease control (DC) at 6 months | 13.2 | 21.5 | 1.6 | 12.5 |
| METHOD 1: No DC at 6 months | 86.8 | 78.5 | 98.4 | 87.5 |
| METHOD 1: No DC at 6 months-Not evaluable/missing | 20.2 | 20.0 | 22.2 | 20.6 |
| METHOD 2: DC at 6 months | 20.2 | 26.2 | 9.5 | 19.1 |
| METHOD 2: No DC at 6 months | 79.8 | 73.8 | 90.5 | 80.9 |
| METHOD 2: No DC at 6 months-Not evaluable/missing | 20.2 | 20.0 | 22.2 | 20.6 |
Disease control rate (DCR) at 12 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD). -Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following randomization. -Method 2: Patients who had a best objective response of CR or PR in the first 24 weeks or who had demonstrated SD for a minimum interval of 16 weeks following randomization.
| % participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| DC at 12 months | 10.1 | 12.3 | 1.6 | 8.6 |
| No DC at 12 months | 89.9 | 87.7 | 98.4 | 91.4 |
| No DC at 12 months-Not evaluable/missing | 20.2 | 20.0 | 22.2 | 20.6 |
Progression status at 6 months based on BICR assessments according to RECIST v1.1 at time of Progression Free Survival (PFS) analysis. Progression was defined as the time from the data of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. -Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. -Progression death refers to death in the absence of RECIST 1.1 progression.
| % participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Progression-Total | 82.0 | 82.1 | 88.1 | 83.5 |
| Total-RECIST 1.1 Progression | 57.9 | 59.7 | 67.2 | 60.7 |
| RECIST 1.1 progression-Target Lesions | 43.6 | 43.3 | 55.2 | 46.4 |
| RECIST 1.1 progression-Non-target lesions | 21.1 | 26.9 | 32.8 | 25.5 |
| RECIST 1.1 progression-New lesions | 26.3 | 20.9 | 26.9 | 25.1 |
| Progression-Death | 24.1 | 22.4 | 20.9 | 22.8 |
| No progression-Total | 18.0 | 17.9 | 11.9 | 16.5 |
| No progression-PD free and still being followed | 14.3 | 13.4 | 4.5 | 11.6 |
| No progression-Censored on Study Day 1 | 1.5 | 0 | 0 | 0.7 |
| No progression-Withdrawn consent | 0.8 | 3.0 | 1.5 | 1.5 |
| No progression- Censored death | 1.5 | 1.5 | 3.0 | 1.9 |
| No progression- Discontinued study | 0 | 0 | 3.0 | 0.7 |
Progression status at 12 months based on BICR assessments according to RECIST v1.1 at time of Progression Free Survival (PFS) analysis. Progression was defined as the time from the data of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. -Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. -Progression death refers to death in the absence of RECIST 1.1 progression.
| % participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Progression-Total | 88.7 | 83.6 | 89.6 | 87.6 |
| Total-RECIST 1.1 Progression | 64.7 | 59.7 | 68.7 | 64.4 |
| RECIST 1.1 progression-Target Lesions | 50.4 | 47.8 | 56.7 | 51.3 |
| RECIST 1.1 progression-Non-target lesions | 23.3 | 28.4 | 32.8 | 27.0 |
| RECIST 1.1 progression-New lesions | 27.1 | 23.9 | 23.9 | 25.5 |
| Progression-Death | 24.1 | 23.9 | 20.9 | 23.2 |
| No progression-Total | 11.3 | 16.4 | 10.4 | 12.4 |
| No progression-PD free and still being followed | 6.8 | 11.9 | 3.0 | 7.1 |
| No progression-Censored death | 3.8 | 0 | 3.0 | 2.6 |
| No progression-Withdrawn consent | 0.8 | 4.5 | 1.5 | 1.9 |
| No progression-Discontinued study | 0 | 0 | 3.0 | 0.7 |
Survival status at time of overall survival analysis. 'Still in survival follow-up' includes patients known to be alive at data cut-off. 'Terminated prior to death' includes patients with unknown survival status or patients who were lost to follow-up.
| % participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Death | 64.7 | 65.7 | 76.1 | 67.8 |
| Still in survival follow-up | 30.1 | 28.4 | 16.4 | 26.2 |
| Terminated prior to death | 5.3 | 6.0 | 7.5 | 6.0 |
| Terminated prior to death-Voluntary discon. | 5.3 | 6.0 | 4.5 | 5.2 |
| Terminated prior to death-Other | 0 | 0 | 3.0 | 0.7 |
Improvement in quality of life was assessed using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires: -The impact of treatment on Health-Related Quality of Life, functioning, and symptoms was evaluated using the EORTC QLQ-C30 v3. -Head and neck cancer-specific symptoms were evaluated using the EORTC QLQ-H\&N35. The symptom and QoL/function improvement rate was defined as the number (%) of patients with 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (a decrease from baseline score ≥10 or EORTC QLQ-C30 scales) in that symptom/function from baseline. For QLQ-H\&N35A a minimum clinically meaningful change was defined as a change in the score from baseline of \>10 for scales/items
| % patients | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab |
|---|---|---|---|
| EORTC QLQ-C30 Function-Physical | 12 (6.7 to 20.8) | 13.6 (6.4 to 26.7) | 5.1 (1.4 to 16.9) |
| EORTC QLQ-C30 Function-Role | 16.3 (10.0 to 25.5) | 16.7 (8.3 to 30.6) | 11.8 (4.7 to 26.6) |
| EORTC QLQ-C30 Function-Cognitive | 25 (16.2 to 36.4) | 29.4 (16.8 to 46.2) | 10.7 (3.7 to 27.2) |
| EORTC QLQ-C30 Function-Emotional | 13.5 (7.9 to 22.1) | 13.6 (6.4 to 26.7) | 2.6 (0.5 to 13.2) |
| EORTC QLQ-C30 Function-Social | 18.3 (11.0 to 28.8) | 15.2 (6.7 to 30.9) | 16.1 (7.1 to 32.6) |
| EORTC QLQ-C30 Symptom-Fatigue | 16.8 (10.9 to 25.0) | 17.3 (9.4 to 29.7) | 7.5 (3.0 to 17.9) |
| EORTC QLQ-C30 Symptom-Pain | 22.8 (15.4 to 32.4) | 20.8 (11.7 to 34.3) | 6.7 (2.3 to 17.9) |
| EORTC QLQ-C30 Symptom-Nausea/vomiting | 22.2 (12.5 to 36.3) | 16.7 (4.7 to 44.8) | 17.6 (6.2 to 41.0) |
| EORTC QLQ-C30 Global health status/QoL | 13.4 (8.3 to 20.9) | 7.3 (2.9 to 17.3) | 3.7 (1.0 to 12.5) |
| EORTC QLQ-H&N35 Scale-Pain | 16.7 (9.8 to 26.9) | 19.4 (9.8 to 35.0) | 8.3 (2.9 to 21.8) |
| EORTC QLQ-H&N35 Scale-Swallowing | 16.0 (9.4 to 25.9) | 13.3 (6.3 to 26.2) | 10.3 (4.1 to 23.6) |
| EORTC QLQ-H&N35 Scale-Senses | 17.8 (10.7 to 28.1) | 24.3 (13.4 to 40.1) | 23.1 (12.6 to 38.3) |
| EORTC QLQ-H&N35 Scale-Speech | 20.2 (13.3 to 29.4) | 9.8 (4.3 to 21.0) | 19.6 (10.7 to 33.2) |
| EORTC QLQ-H&N35 Scale-Social eating | 21.3 (13.7 to 31.4) | 20.0 (10.9 to 33.8) | 15.0 (7.1 to 29.1) |
| EORTC QLQ-H&N35 Scale-Social contact | 22.6 (14.0 to 34.4) | 5.9 (1.6 to 19.1) | 13.0 (4.5 to 32.1) |
| EORTC QLQ-H&N35 Scale-Sexuality | 16.2 (9.5 to 26.2) | 9.5 (3.8 to 22.1) | 9.5 (3.8 to 22.1) |
Duration of objective response in patients with objective response based on BICR assessments according to RECIST v1.1. Duration of response was the time from the first documentation of Complete response/Partial response (which was subsequently confirmed) until the date of progression, death, or the last evaluable RECIST assessment for patients that did not progress. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off (per RECIST v1.1 as assessed by BICR).
| Participants | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| No. progressed or died within 12 months | 5 | 2 | 0 | 7 |
| No. progressed or died after 12 months | 0 | 0 | 0 | 0 |
Collected over AEs and SAEs were collected from time the informed consent was signed through 90 days after the last dose of the last study treatment or until another therapy was initiated.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MEDI4736 AND TREMELIMUMAB COMBINATION | 86/133 (64.7%) | 59/133 (44.4%) | 110/133 (82.7%) |
| MEDI4736 | 44/67 (65.7%) | 18/65 (27.7%) | 52/65 (80%) |
| Tremelimumab | 51/67 (76.1%) | 25/65 (38.5%) | 59/65 (90.8%) |
| Event | MEDI4736 AND TREMELIMUMAB COMBINATION | MEDI4736 | Tremelimumab |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/133 | 0/65 | 5/65 |
| PneumoniaInfections and infestations | 9/133 | 1/65 | 1/65 |
| DysphagiaGastrointestinal disorders | 1/133 | 1/65 | 2/65 |
| Pneumonia bacterialInfections and infestations | 0/133 | 0/65 | 2/65 |
| DizzinessNervous system disorders | 0/133 | 2/65 | 0/65 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/133 | 1/65 | 2/65 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 3/133 | 0/65 | 2/65 |
| Lung infectionInfections and infestations | 4/133 | 1/65 | 1/65 |
| DehydrationMetabolism and nutrition disorders | 4/133 | 1/65 | 1/65 |
| HypercalcaemiaMetabolism and nutrition disorders | 4/133 | 1/65 | 0/65 |
| Event | MEDI4736 AND TREMELIMUMAB COMBINATION | MEDI4736 | Tremelimumab |
|---|---|---|---|
| FatigueGeneral disorders | 25/133 | 19/65 | 12/65 |
| NauseaGastrointestinal disorders | 18/133 | 7/65 | 18/65 |
| DiarrhoeaGastrointestinal disorders | 27/133 | 12/65 | 14/65 |
| Decreased appetiteMetabolism and nutrition disorders | 25/133 | 10/65 | 10/65 |
| PyrexiaGeneral disorders | 16/133 | 5/65 | 12/65 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 14/133 | 10/65 | 12/65 |
| AnaemiaBlood and lymphatic system disorders | 20/133 | 11/65 | 11/65 |
| AstheniaGeneral disorders | 21/133 | 10/65 | 8/65 |
| HypothyroidismEndocrine disorders | 15/133 | 9/65 | 6/65 |
| ConstipationGastrointestinal disorders | 18/133 | 9/65 | 8/65 |
Full analysis set - all randomized patients
| Age, Categorical(Participants) | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 88 | 46 | 42 | 176 |
| >=65 years | 45 | 21 | 25 | 91 |
| Age, Continuous(years) | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Median | 62 (26 to 81) | 62 (23 to 82) | 61 (42 to 77) | 61 (23 to 82) |
| Sex: Female, Male(Participants) | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Female | 20 | 13 | 14 | 47 |
| Male | 113 | 54 | 53 | 220 |
| Race (NIH/OMB)(Participants) | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 4 | 3 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 3 | 1 | 10 |
| White | 115 | 58 | 57 | 230 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 3 | 7 | 18 |
| Race/Ethnicity, Customized(Participants) | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Ethnic group - Hispanic or Latino | 8 | 2 | 5 | 15 |
| Ethnic group - Not Hispanic or Latino | 119 | 64 | 58 | 241 |
| Ethnic group - Total | 127 | 66 | 63 | 256 |
| Asian ethnic group - Asian (not Chinese/Japanese) | 3 | 2 | 1 | 6 |
| Asian ethnic group - Chinese | 1 | 1 | 1 | 3 |
| Asian ethnic group - Total | 4 | 3 | 2 | 9 |
| Unknown or not reported | 2 | 0 | 2 | 4 |
| Negative PD-L1 status(Participants) | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| PD-L1 negative patients | 133 | 67 | 67 | 267 |
| HPV status(Participants) | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Positive | 39 | 18 | 18 | 75 |
| Negative | 94 | 49 | 49 | 192 |
| Use of nicotine (other than cigarettes)(Participants) | MEDI4736 + Tremelimumab | MEDI4736 | Tremelimumab | Total |
|---|---|---|---|---|
| Yes | 1 | 1 | 0 | 2 |
| No | 132 | 66 | 67 | 265 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 125 sites across 15 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2015 to primary completion in Sep 2016, 17 months.
Results were first posted in Jun 2018, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Tremelimumab